Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.87 USD | +4.31% | +0.52% | -82.38% |
Feb. 20 | Tenax Therapeutics Secures Global Rights for Levosimendan | MT |
Feb. 20 | Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement | CI |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 6.83M |
---|---|---|---|---|---|
Net income 2023 * | -7M | Net income 2024 * | -12M | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.13
x | P/E ratio 2024 * |
-0.61
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 16.5% |
1 day | +4.31% | ||
1 week | +0.52% | ||
Current month | -15.69% | ||
1 month | -7.42% | ||
3 months | -83.49% | ||
6 months | -83.32% | ||
Current year | -82.38% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 21-07-13 | |
Director of Finance/CFO | 69 | Jan. 10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 14-04-03 |
June Almenoff
BRD | Director/Board Member | 67 | 21-02-24 |
Declan Doogan
BRD | Director/Board Member | 72 | 21-02-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 3.87 | +4.31% | 31,764 |
24-03-26 | 3.71 | +0.27% | 75,226 |
24-03-25 | 3.7 | -3.14% | 32,776 |
24-03-22 | 3.82 | -2.55% | 25,185 |
24-03-21 | 3.92 | +1.82% | 65,005 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.38% | 6.83M | |
+9.16% | 45.97B | |
+53.75% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |